6-bromo-9H-carbazol-3-amine | 1262853-29-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-bromo-9H-carbazol-3-amine
• CAS: 1262853-29-1
• 化学式: C₁₂H₉BrN₂
• 分子量: 261.121
• InChiKey: GCQUDBPONMTEOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-bromo-9H-carbazol-3-amine 在 氧气 、 copper(I) bromide 作用下， 以 二甲基亚砜 为溶剂， 反应 6.0h， 以85%的产率得到
  参考文献：
  名称：

  Copper-Catalyzed Aerobic Oxidative Coupling of Aminocarbazoles and Aminoindoles: Synthesis of Diindolophenazines and Dipyrrolophenazines

  摘要：

  我们开发了一种简便的方法，通过在80°C下，在催化量的CuBr（10摩尔%）存在下，在DMSO中并开放于空气中，分别利用3-氨基咪和2,3-二甲基-5-氨基吲哚衍生物的 aerobic oxidative coupling 来合成二吲唑并菲嗪和二吡咯并菲嗪衍生物。

  DOI：

  10.1055/s-0030-1258818

文献信息

• Anti-depression compounds
  申请人：Board of Regents of the University of Texas System

  公开号：US10183011B2

  公开（公告）日：2019-01-22

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

  本技术一般涉及刺激神经发生（如出生后神经发生，包括出生后海马和下丘脑神经发生）和/或保护神经细胞免于细胞死亡的化合物和方法。本文公开了多种化合物。体内活性测试表明，这些化合物可能对神经精神疾病和/或神经退行性疾病有治疗作用，如精神分裂症、重度抑郁症、双相情感障碍、正常衰老、癫痫、创伤性脑损伤、创伤后应激障碍、帕金森病、阿尔茨海默病、唐氏综合征、脊髓小脑共济失调、肌萎缩侧索硬化症等、肌萎缩性脊髓侧索硬化症、亨廷顿氏病、中风、放射治疗、慢性压力、滥用神经活性药物、视网膜变性、脊髓损伤、周围神经损伤、与各种疾病相关的生理性体重减轻，以及与正常衰老、化疗等相关的认知能力下降。
• PRO-NEUROGENIC COMPOUNDS
  申请人：Board of Regents of the University of Texas System

  公开号：EP2590647B1

  公开（公告）日：2017-11-08
• Anti-depression Compounds
  申请人：Board of Regents of the University of Texas System

  公开号：US20170157092A1

  公开（公告）日：2017-06-08

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
• Pro-Neurogenic Compounds
  申请人：Board of Regents of the Univeristy of Texas System

  公开号：US20180127367A1

  公开（公告）日：2018-05-10

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
• US6399631B1
  申请人：——

  公开号：US6399631B1

  公开（公告）日：2002-06-04